Routine Capillary Hemoglobin Testing in United Kingdom Commercial Pilot Applicants.

IF 0.8 4区 医学 Q4 BIOPHYSICS
Philip P MacMillan
{"title":"Routine Capillary Hemoglobin Testing in United Kingdom Commercial Pilot Applicants.","authors":"Philip P MacMillan","doi":"10.3357/AMHP.6894.2026","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>United Kingdom regulations mandate hemoglobin (Hb) testing at each commercial (Class 1) pilot medical examination. The utility of point-of-care finger-prick capillary Hb in determining aeromedical certification outcomes remains unquantified.</p><p><strong>Methods: </strong>A retrospective review was conducted of all initial Class 1 medical examinations recorded in the UK Civil Aviation Authority medical records system from April 2021 to March 2025. Applicants with capillary Hb outside thresholds (male <115 g · L-1, female <105 g · L-1, all >180 g · L-1) were identified. Clinical pathways, confirmatory testing, and fitness outcomes were analyzed.</p><p><strong>Results: </strong>Of 3353 applicants, 48 (1.43%; 95% confidence interval 1.08-1.89) had abnormal capillary Hb (33 high, 15 low). Of those, 35 (73%) were certified fit, 1 (2%) was assessed as unfit due to predeclared sickle cell disease, and 12 (25%) were lost to follow-up prior to fitness determination. Only 3 of 36 applicants receiving a fitness outcome were assessed as unfit or required treatment before certification (positive predictive value 8.3%; 95% confidence interval 2.9-21.8%). Among 13 applicants undergoing confirmatory venous testing, 12 returned normal results. No cases of polycythemia were identified.</p><p><strong>Discussion: </strong>Capillary Hb screening did not identify conditions leading to unfit assessment beyond predeclared disease. The sole unfit determination resulted from a disqualifying history before testing. Two applicants (0.06%) required treatment before certification; whether these would have been detected through clinical evaluation alone is uncertain. These findings suggest limited utility for this screening practice in asymptomatic initial pilot applicants, though value in serial assessments of established pilots warrants further investigation. MacMillan PP. Routine capillary hemoglobin testing in United Kingdom commercial pilot applicants. Aerosp Med Hum Perform. 2026; 97(8):601-606.</p>","PeriodicalId":7463,"journal":{"name":"Aerospace medicine and human performance","volume":"97 8","pages":"601-606"},"PeriodicalIF":0.8000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aerospace medicine and human performance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3357/AMHP.6894.2026","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOPHYSICS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: United Kingdom regulations mandate hemoglobin (Hb) testing at each commercial (Class 1) pilot medical examination. The utility of point-of-care finger-prick capillary Hb in determining aeromedical certification outcomes remains unquantified.

Methods: A retrospective review was conducted of all initial Class 1 medical examinations recorded in the UK Civil Aviation Authority medical records system from April 2021 to March 2025. Applicants with capillary Hb outside thresholds (male <115 g · L-1, female <105 g · L-1, all >180 g · L-1) were identified. Clinical pathways, confirmatory testing, and fitness outcomes were analyzed.

Results: Of 3353 applicants, 48 (1.43%; 95% confidence interval 1.08-1.89) had abnormal capillary Hb (33 high, 15 low). Of those, 35 (73%) were certified fit, 1 (2%) was assessed as unfit due to predeclared sickle cell disease, and 12 (25%) were lost to follow-up prior to fitness determination. Only 3 of 36 applicants receiving a fitness outcome were assessed as unfit or required treatment before certification (positive predictive value 8.3%; 95% confidence interval 2.9-21.8%). Among 13 applicants undergoing confirmatory venous testing, 12 returned normal results. No cases of polycythemia were identified.

Discussion: Capillary Hb screening did not identify conditions leading to unfit assessment beyond predeclared disease. The sole unfit determination resulted from a disqualifying history before testing. Two applicants (0.06%) required treatment before certification; whether these would have been detected through clinical evaluation alone is uncertain. These findings suggest limited utility for this screening practice in asymptomatic initial pilot applicants, though value in serial assessments of established pilots warrants further investigation. MacMillan PP. Routine capillary hemoglobin testing in United Kingdom commercial pilot applicants. Aerosp Med Hum Perform. 2026; 97(8):601-606.

英国商业飞行员申请人的常规毛细血管血红蛋白检测。
简介:英国法规要求在每次商业(1类)试点医疗检查中检测血红蛋白(Hb)。在确定航空医学认证结果的护理点指刺毛细血管Hb的效用仍未量化。方法:回顾性分析英国民航局病历系统中从2021年4月至2025年3月记录的所有首次1类体检。确定毛细血管Hb超出阈值的申请人(男性180 g·L-1)。分析临床途径、验证性测试和适应度结果。结果:在3353名申请者中,48名(1.43%;95%置信区间1.08-1.89)有毛细血管Hb异常(33名高,15名低)。其中,35人(73%)被证明是健康的,1人(2%)被评估为由于预先声明的镰状细胞病而不健康,12人(25%)在健康确定之前失去了随访。在36名获得健身结果的申请人中,只有3人在认证前被评估为不适合或需要治疗(阳性预测值8.3%;95%置信区间2.9-21.8%)。在13名接受确认性静脉试验的申请人中,12名结果正常。未发现红细胞增多症病例。讨论:毛细管Hb筛查没有发现导致不适合评估的条件超出预先宣布的疾病。唯一的不合格判定是由于检测前的不合格史。2名申请人(0.06%)在认证前需要处理;仅通过临床评估是否能发现这些是不确定的。这些发现表明,这种筛选实践在无症状的初始飞行员申请者中的效用有限,尽管对已建立的飞行员进行系列评估的价值值得进一步调查。麦克米伦PP.常规毛细管血红蛋白测试在英国商业试点申请人。航空航天Med Hum执行。2026;97(8): 601 - 606。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Aerospace medicine and human performance
Aerospace medicine and human performance PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -MEDICINE, GENERAL & INTERNAL
CiteScore
1.10
自引率
22.20%
发文量
272
期刊介绍: The peer-reviewed monthly journal, Aerospace Medicine and Human Performance (AMHP), formerly Aviation, Space, and Environmental Medicine, provides contact with physicians, life scientists, bioengineers, and medical specialists working in both basic medical research and in its clinical applications. It is the most used and cited journal in its field. It is distributed to more than 80 nations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书